BridgeBio Pharma (NASDAQ: BBIO) CEO offloads 44,980 shares

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) reported that Chief Executive Officer and director Neil Kumar filed a Form 4 disclosing open-market sales of a total of 44,980 shares of common stock on August 18–19, 2026. Some shares were sold directly and others were sold by the Kumar Haldea Family Irrevocable Trust, where he is a co‑trustee. The transactions were effected pursuant to a Rule 10b5-1 sales plan adopted on May 13, 2026, with reported weighted average sale prices in the low-to-mid $80s per share. After these transactions, separately reported indirect holdings include 3,568,447 shares held by the Kumar Haldea Revocable Trust and 750,000 shares held by the NK 2026 GRAT, with Kumar disclaiming beneficial ownership of certain trust-held shares except to the extent of his pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 44,980 shares

Net Sell 9 txns

Insider Kumar Neil

Role Chief Executive Officer

Sold 44,980 shs ($3.73M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F6, F7	8,100	$83.8588	$679K
Sale	Common Stock F1, F8, F7	1,800	$84.6867	$152K
Sale	Common Stock F1, F7	100	$85.65	$9K
Sale	Common Stock F1, F2	1,900	$81.1494	$154K
Sale	Common Stock F1, F3	17,279	$82.2104	$1.42M
Sale	Common Stock F1, F4	14,602	$82.9922	$1.21M
Sale	Common Stock F1, F5	1,199	$83.7732	$100K
holding	Common Stock F7	--	--	--
holding	Common Stock F9	--	--	--

Holdings After Transaction: Common Stock — 243,327 shares (Direct); Common Stock — 505,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 3,568,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 750,000 shares (Indirect, By NK 2026 GRAT)

Footnotes (9)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
2. F2. Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. F3. Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4. F4. Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5. F5. Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
6. F6. Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
7. F7. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
8. F8. Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
9. F9. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.

Key Figures

Shares sold: 44,980 shares Sale price per share: $81.1494 per share Sale price per share: $82.2104 per share +4 more

7 metrics

Shares sold 44,980 shares Total common shares sold in reported transactions on August 18–19, 2026

Sale price per share $81.1494 per share Direct sale of 1,900 common shares on August 18, 2026

Sale price per share $82.2104 per share Direct sale of 17,279 common shares on August 18, 2026

Sale price per share $83.8588 per share Indirect sale of 8,100 common shares on August 19, 2026 by family trust

Indirect holdings 3,568,447 shares Common shares held by the Kumar Haldea Revocable Trust after transactions

Indirect holdings 750,000 shares Common shares held by the NK 2026 GRAT after transactions

Rule 10b5-1 plan adoption date May 13, 2026 Date Neil Kumar adopted the sales plan governing these transactions

Key Terms

Rule 10b5-1 sales plan, weighted average sale price, pecuniary interest, grantor retained annuity trust

4 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted"

weighted average sale price financial

"Represents the weighted average sale price of the shares sold from"

pecuniary interest financial

"disclaims beneficial ownership of these shares except to the extent of his pecuniary interest"

grantor retained annuity trust financial

"These shares are held by the NK 2026 GRAT, a grantor retained annuity trust"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

FAQ

What insider trading did BBIO CEO Neil Kumar report on this Form 4?

Neil Kumar reported sales of 44,980 shares of BridgeBio Pharma common stock on August 18–19, 2026, through a combination of direct holdings and shares held by the Kumar Haldea Family Irrevocable Trust, where he serves as a co‑trustee.

At what prices were the BBIO shares sold by Neil Kumar in August 2026?

The reported transactions show per‑share prices such as $81.1494, $82.2104, $82.9922, $83.7732, $83.8588, $84.6867, and $85.6500, with accompanying footnotes describing weighted average sale price ranges within the low-to-mid $80s per share.

Were Neil Kumar’s August 2026 BBIO stock sales made under a Rule 10b5-1 plan?

Yes. A footnote states that these transactions were effected pursuant to a Rule 10b5-1 sales plan adopted by Neil Kumar on May 13, 2026, and the Form 4 indicates the Rule 10b5‑1 checkbox as affirmed.

How many BridgeBio (BBIO) shares are reported as indirectly held by Neil Kumar after these transactions?

The Form 4 reports 3,568,447 shares of common stock held by the Kumar Haldea Revocable Trust and 750,000 shares held by the NK 2026 GRAT, both reported as indirect holdings, with beneficial ownership in certain trust shares disclaimed except for Kumar’s pecuniary interest.

What role do trusts play in Neil Kumar’s BBIO share ownership?

Some shares are held by the Kumar Haldea Family Irrevocable Trust, from which shares were sold, and by the Kumar Haldea Revocable Trust and the NK 2026 GRAT. Neil Kumar is a trustee or co‑trustee, and he disclaims beneficial ownership of certain trust shares except to the extent of his pecuniary interest.

Does Neil Kumar fully own the trust-held BBIO shares reported on this Form 4?

No. Footnotes state that Neil Kumar disclaims beneficial ownership of shares held by certain trusts, including the Kumar Haldea Family Irrevocable Trust and the NK 2026 GRAT, except to the extent of his pecuniary interest in those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 04:31 PM Accepted by SEC EDGAR 08/20/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S(1)		1,900	D	$81.1494(2)	276,407	D
Common Stock	08/18/2026		S(1)		17,279	D	$82.2104(3)	259,128	D
Common Stock	08/18/2026		S(1)		14,602	D	$82.9922(4)	244,526	D
Common Stock	08/18/2026		S(1)		1,199	D	$83.7732(5)	243,327	D
Common Stock	08/19/2026		S(1)		8,100	D	$83.8588(6)	507,586	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(7)
Common Stock	08/19/2026		S(1)		1,800	D	$84.6867(8)	505,786	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(7)
Common Stock	08/19/2026		S(1)		100	D	$85.65	505,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(7)
Common Stock								3,568,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(7)
Common Stock								750,000	I	By NK 2026 GRAT(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.

2. Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

8. Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

9. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)